Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 4:07 pm Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,189,719 9.9% | 69,719 (+3.29%) | View |
| 2023-02-14 06:15 am Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 2,124,694 11% | -4,139,726 (-66.08%) | View |
| 2023-02-10 7:41 pm Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | Artal International S.C.A. | 1,463,829 7.2% | -2,036,171 (-58.18%) | View |
| 2023-01-27 6:01 pm Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 1,439,379 6.9% | -2,491,141 (-63.38%) | View |
| 2023-01-25 5:00 pm Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,253,828 6.04% | 1,253,828 (New Position) | View |
| 2022-11-10 11:55 am Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | FMR LLC | 104,614 0.516% | -5,693,262 (-98.20%) | View |
| 2022-09-20 4:35 pm Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | Avidity Partners Management LP | 2,120,000 9.9% | 2,120,000 (New Position) | View |
| 2022-09-19 4:07 pm Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | Deep Track Capital LP | 699,281 9.99% | 699,281 (New Position) | View |
| 2022-09-16 4:31 pm Sale | 13D | Syros Pharmaceuticals, Inc. SYRS | TYME TECHNOLOGIES INC. TYME | 0 0% | -17,460,552 (Position Closed) | View |
| 2022-07-13 5:15 pm Purchase | 13D | Syros Pharmaceuticals, Inc. SYRS | TYME TECHNOLOGIES INC. TYME | 17,460,552 28% | 17,460,552 (New Position) | View |
| 2022-07-13 5:10 pm Purchase | 13D | TYME TECHNOLOGIES INC. TYME | Syros Pharmaceuticals Inc. SYRS | 17,819,723 9.9% | 17,819,723 (New Position) | View |
| 2022-07-08 4:57 pm Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | BlackRock Inc. BLK | 1,524,309 2.4% | -2,707,959 (-63.98%) | View |
| 2022-04-11 09:01 am Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | FMR LLC | 5,797,876 9.298% | -3,534,921 (-37.88%) | View |
| 2022-02-14 06:41 am Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | Bain Capital Life Sciences Fund II L.P. | 6,264,420 11% | 479,384 (+8.29%) | View |
| 2022-02-14 06:06 am Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | Nikko Asset Management Americas Inc. | 0 0% | -4,381,992 (Position Closed) | View |
| 2022-02-11 4:17 pm Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 3,930,520 6.3% | 897,395 (+29.59%) | View |
| 2022-02-11 06:28 am Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | Artal International S.C.A. | 3,500,000 5.6% | 3,500,000 (New Position) | View |
| 2022-02-09 10:01 am Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | FMR LLC | 9,332,797 14.999% | 2,420,462 (+35.02%) | View |
| 2022-02-04 06:09 am Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | Sumitomo Mitsui Trust Holdings Inc. | 0 0% | -4,381,992 (Position Closed) | View |
| 2022-02-03 4:41 pm Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | BlackRock Inc. BLK | 4,232,268 6.8% | 906,708 (+27.26%) | View |